Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Vinagre

Internal Medicine Indian Orchard, MA Medical Doctor

NPI 1053329045 CMS profile 229278

811 Worcester St, Indian Orchard, MA 01151

Open in the dashboard

General payments

$12,329

691 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Vinagre of Indian Orchard, MA is reported in the CMS Open Payments database as having received $12,329 across 691 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,817 92
2024 General $1,759 91
2023 General $2,186 112
2022 General $1,610 93
2021 General $1,886 112
2020 General $1,280 73
2019 General $1,791 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Vinagre
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jose Vinagre were reported at $1,817. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jose Vinagre Internal Medicine median Middle half National median
2019 $1,791 $159 $48–$570 $163
2020 $1,280 $119 $33–$402 $114
2021 $1,886 $135 $37–$521 $132
2022 $1,610 $141 $42–$496 $149
2023 $2,186 $149 $45–$519 $160
2024 $1,759 $154 $47–$537 $164
2025 $1,817 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,296 111 payments
  2. Pfizer Inc. $1,344 105 payments
  3. Novo Nordisk Inc $1,297 70 payments
  4. Lilly USA, LLC $1,198 69 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $805 47 payments
  6. GlaxoSmithKline, LLC. $671 40 payments
  7. Abbott Laboratories $597 29 payments
  8. Merck Sharp & Dohme Corporation $493 29 payments
  9. Janssen Pharmaceuticals, Inc $485 31 payments
  10. Exact Sciences Corporation $440 23 payments
  11. Other $2,703 137 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,207 687 payments
  2. Education $122 4 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $978 46 payments
  2. ELIQUIS $848 64 payments
  3. Ozempic $814 43 payments
  4. TRELEGY ELLIPTA $644 38 payments
  5. RYBELSUS $598 31 payments
  6. JARDIANCE $485 29 payments
  7. SYMBICORT $484 21 payments
  8. FreeStyle Libre 3 $481 23 payments
  9. XARELTO $465 29 payments
  10. MOUNJARO $451 25 payments
  11. Other $9,988 617 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 126 drugs

Part D claims

8,515

Median for Internal Medicine: 777

Drug cost

$567,386

Median for Internal Medicine: $73,373

Branded share of claims

18.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 135 $153,790
Farxiga Dapagliflozin Propanediol Brand 63 $65,275
Ozempic Semaglutide Brand 36 $35,261
Januvia Sitagliptin Phosphate Brand 19 $22,440
Jardiance Empagliflozin Brand 16 $19,574
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $19,451
Linzess Linaclotide Brand 16 $19,449
Janumet Sitagliptin Phos/Metformin Hcl Brand 15 $15,776
Trulicity Dulaglutide Brand 15 $15,546
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 80 $12,486

The 10 drugs with the highest cost, of 126 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$55,396

Medicare's payments for the services billed

Medicare patients

241

Average age 76

Services billed

823

131 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 35%
Diabetes 22%
Chronic kidney disease 22%
Depression 20%
Atrial fibrillation 17%
Ischemic heart disease 15%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $99
  • Boehringer Ingelheim Pharmaceuticals, Inc. $87
$186 16 —
MOUNJARO
  • Lilly USA, LLC $154
$154 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $137
$137 63 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $121
$121 11 —
AREXVY
  • GlaxoSmithKline, LLC. $80
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

691 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record